Bloomberg Law
Jan. 15, 2019, 3:35 PM

Roche Sues Laurus to Block Copies of Esbriet Lung-Disease Drug

Christopher  Yasiejko
Christopher Yasiejko
Bloomberg Editorial

Roche’s Genentech unit said Laurus Labs’ proposed generic version of a drug for the treatment of a lung disease called idiopathic pulmonary fibrosis would infringe 19 patents.

Roche is seeking a court order blocking copies until after the latest of the patents’ expirations, and to collect cash compensation if copies are made before then, according to complaint filed Jan. 14 in federal court in Wilmington, Del.

IPF results in scarring of the lungs, makes breathing difficult, and prevents vital organs from receiving enough oxygen to work properly. The median survival rate is 2-5 years after diagnosis. IPF is irreversible, with ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.